NICE Likes Janssen’s Olysio, But Raises Cost Concerns Over Sovaldi Link
This article was originally published in The Pink Sheet Daily
Executive Summary
NICE could recommend Janssen's Olysio for HCV, but excludes genotype 4, and questions the cost of linking the drug with Gilead's Sovaldi.